Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Radiotherapy-Activated NBTXR3 Shows Survival Benefit in Elderly Patients With Head and Neck Squamous Cell Carcinoma

October 26th 2021

The administration of NBTXR3 monotherapy activated by radiotherapy resulted in encouraging survival improvements in difficult-to-treat elderly and frail patients with locally advanced head and neck squamous cell carcinoma who are ineligible for cisplatin and intolerant to cetuximab.

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer

October 21st 2021

Treatment with the small molecule oral immunomodulator EC-18 resulted in a reduction in both the duration and incidence of severe oral mucositis in patients with head and neck cancer who are undergoing concurrent chemoradiation.

Implementable Changes Could Improve QOL With Radiation-Related Mucositis in Head and Neck Cancer

October 20th 2021

Anurag Singh, MD, discussed the potential advantage to treating patients with radiation therapy at specific times of day, how the utilization of prophylactic gabapentin has decreased the need for narcotics in managing oral mucositis in patients with head and neck cancer, and the potential use of single-fraction radiation therapy in oncology.

Avasopasem Misses the Mark for Radiotherapy-Induced Severe Oral Mucositis in Head and Neck Cancer

October 19th 2021

The dismutase mimetic avasopasem manganese was not found to significantly reduce the incidence of severe oral mucositis in patients with locally advanced head and neck cancer who were receiving standard-of-care radiotherapy, missing the primary end point of the phase 3 ROMAN trial.

Dr. Singh on the Potential Effects of Radiation Timing in Head and Neck Cancer

October 18th 2021

Anurag Singh, MD, discusses the potential effects of radiation timing in head and neck cancer.

Cabozantinib Maintains PFS Advantage in Pretreated Differentiated Thyroid Cancer

September 29th 2021

Cabozantinib demonstrated a sustained benefit in progression-free survival vs placebo in patients with previously treated, radioactive iodine–refractory differentiated thyroid cancer, regardless of prior exposure to sorafenib or lenvatinib.

FDA Approves Cabozantinib for Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

September 17th 2021

The FDA has approved cabozantinib for the treatment of adult and pediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid cancer that has progressed after prior VEGF-targeted therapy and who are radioactive iodine–refractory or ineligible.

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

September 2nd 2021

Dr. Sosa discusses the rise in thyroid cancer cases, patient risk factors, the financial challenges associated with long-term treatment and testing, and future research directions in the field.

Rolling Submission of BLA to FDA Completed for Toripalimab Plus Chemotherapy in Metastatic Nasopharyngeal Carcinoma

September 1st 2021

The rolling submission of a biologics license application to support the approval of both toripalimab plus gemcitabine- and cisplatin-based chemotherapy as a first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, as well as toripalimab monotherapy for the second-line or beyond treatment of patients with recurrent or metastatic nasopharyngeal carcinoma after platinum-based chemotherapy has been completed.

Fox Chase’s Camille Ragin Awarded SPORE Grant to Examine Racial Differences in Risk for Head and Neck Cancer Patients

August 30th 2021

Fox Chase Cancer Center researcher Camille Ragin, PhD, MPH, was recently awarded a Specialized Program of Research Excellence grant of $50,000 for a pilot project examining differences in risk and disease course for Black versus white head and neck cancer patients.

FDA Grants Breakthrough Therapy Designation for Toripalimab for Frontline Nasopharyngeal Carcinoma

August 12th 2021

The FDA has granted a breakthrough therapy designation to toripalimab for single-agent use in combination with gemcitabine and cisplatin in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Priority Review to Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer

August 5th 2021

The FDA has granted a priority review designation to a supplemental new drug application for cabozantinib for the treatment of patients with differentiated thyroid cancer who have progressed after previous therapy and who are radioactive iodine refractory.

Managing Adverse Events With Tipifarnib

July 19th 2021

Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.

Future Directions in HRAS-Mutated Head and Neck Cancer

July 19th 2021

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.

Pivotal AIM-HN Clinical Trial of Tipifarnib in HNSCC

July 19th 2021

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.

Tipifarnib in HRAS-Mutated HNSCC

July 19th 2021

Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.

Molecular Testing in HNSCC

July 19th 2021

Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.

The Evolving Treatment Landscape of HNSCC

July 19th 2021

A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.

Nivolumab/Ipilimumab Misses OS End Points in Frontline Head and Neck Cancer, But Shows Trend Toward Benefit in Subset

July 16th 2021

Nivolumab plus ipilimumab did not significantly improve overall survival over the EXTREME regimen in the frontline treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck, missing the primary end points of the phase 3 CheckMate-651 trial.

Belapectin/Pembrolizumab Shows Early Activity, Tolerability in Metastatic Melanoma & Head and Neck Cancer

July 11th 2021

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma and head and neck cancer.